Partnership with China Prompts Change in Care for High-Risk Type of Leukemia

Newswise imageResearchers from St. Jude Children’s Research Hospital and the Chinese Children’s Cancer Group led the first randomized, Phase III clinical trial comparing targeted therapies for acute lymphoblastic leukemia (ALL) driven by the Philadelphia chromosome. Results showed that the drug dasatinib provides more benefit than the standard of care, which led to changes in the way this leukemia is treated. The findings were reported today in JAMA Oncology.

Source link

Related posts

CHOP Nurse-Researcher Presents the Spatz 10-Step System as a National Model for Breastfeeding Vulnerable Babies


Estimated 2.5% of U.S. Kids Have Had TBI in Their Lifetime


Percept PC Deep Brain Neurostimulator with BrainSense Cleared in Europe


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy